Advertisement

Tumor Biology

, Volume 37, Issue 12, pp 15937–15947 | Cite as

Reversal effect of ouabain on multidrug resistance in esophageal carcinoma EC109/CDDP cells by inhibiting the translocation of Wnt/β-catenin into the nucleus

  • Yucheng Shen
  • Qinghua Wang
  • Ye Tian
Original Article

Abstract

The incidence of esophageal carcinoma is increasing throughout the world. A major obstacle to its treatment is acquired multidrug resistance (MDR) which results in the failure of chemotherapy and patient relapse. Here, we identified that ouabain is capable of reversing MDR to cisplatin (CDDP) in EC109/CDDP cells and explore the possible mechanisms of action. The parental and the MDR cell lines were both sensitive to ouabain with 50 % inhibitory concentration (IC50) values of 258.11 and 710.63 nM, respectively. Cisplatin cytotoxicity increased in the EC109/CDDP cells by the addition of ouabain which helps promote CDDP-induced apoptosis. Ouabain at 20 nM effectively reduced the IC50 of CDDP in EC109/CDDP cells from 36.54 to 3.39 μM. This represents a 10.78-fold increase in sensitization to CDDP. We also found that ouabain was capable of down regulating the expression of P-glycoprotein (P-gp) and Bcl-2 in a dose- and time-dependent manner. Finally, the results indicated that ouabain suppressed Wnt luciferase report (TOPFlash) activity obviously in EC109/CDDP and depressed the translocation of β-catenin into the nucleus. Moreover, ouabain showed reversal effect of MDR to CDDP in nude mouse xenograft model, and reduced the protein level of β-catenin (Y333) in tumor tissue of CDDP plus ouabain group. All data proved that ouabain has a potent β-catenin-dependent anti-MDR effect.

Keywords

Ouabain Multidrug resistance Esophageal carcinoma Wnt/β-catenin 

Notes

Acknowledgments

The study was supported by Jiangsu Provincial Special Program of Clinical Medical Science (BL2014040), Suzhou Science and Technology Development Program (SZS201509), and Natural Science Foundation of the Jiangsu Higher Education Institutions of China (11KJB180010).

Compliance with ethical standards

All animal studies were carried out in compliance with the Guide for the Care and Use of Laboratory Animals of Nantong University, China.

Conflict of interest

None.

Supplementary material

13277_2016_5437_Fig6_ESM.gif (95 kb)
Fig. 1

Effect of ouabain on EC109/CDDP cell cycle was detected by flow cytometry and western blot. (GIF 94 kb)

13277_2016_5437_MOESM1_ESM.tif (310 kb)
High resolution image (TIFF 309 kb)
13277_2016_5437_Fig7_ESM.gif (303 kb)
Fig. 2

H&E stains the structure of mice liver. (GIF 303 kb)

13277_2016_5437_MOESM2_ESM.tif (1021 kb)
High resolution image (TIFF 1020 kb)
13277_2016_5437_Fig8_ESM.gif (15 kb)
Table. 1

Examine the level of ALT and AST in mice liver by ELISA. (GIF 14 kb)

13277_2016_5437_MOESM3_ESM.tif (22 kb)
High resolution image (TIFF 21 kb)

References

  1. 1.
    Parkin DM. International variation. Oncogene. 2004;23:6329–40.CrossRefPubMedGoogle Scholar
  2. 2.
    HB e-S. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin N Am. 2002;31:421–40 viii.CrossRefGoogle Scholar
  3. 3.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer S. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29.CrossRefPubMedGoogle Scholar
  4. 4.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.CrossRefPubMedGoogle Scholar
  6. 6.
    Rajasekaran AK, Rajasekaran SA. Role of Na-K-ATPase in the assembly of tight junctions. American Journal of Physiology Renal Physiology. 2003;285:F388–96.CrossRefPubMedGoogle Scholar
  7. 7.
    Callaghan R, Ford RC, Kerr ID. The translocation mechanism of p-glycoprotein. FEBS Lett. 2006;580:1056–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Zandvliet M, Teske E, Schrickx JA. Multi-drug resistance in a canine lymphoid cell line due to increased p-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicology In Vitro: an International Journal Published in Association with BIBRA. 2014;28:1498–506.CrossRefGoogle Scholar
  9. 9.
    Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013;25:254–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS, Rustgi AK. Wnt-1 but not epidermal growth factor induces beta-catenin/t-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 2002;62:277–82.PubMedGoogle Scholar
  11. 11.
    Nakanishi Y, Ochiai A, Akimoto S, Kato H, Watanabe H, Tachimori Y, Yamamoto S, Hirohashi S. Expression of e-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: Immunohistochemical analysis of 96 lesions. Oncology. 1997;54:158–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Hsu PC, Hung HC, Liao YF, Liu CC, Tsay GJ, Liu GY. Ornithine decarboxylase attenuates leukemic chemotherapy drugs-induced cell apoptosis and arrest in human promyelocytic hl-60 cells. Leuk Res. 2008;32:1530–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions and structure of abc transporters: implications for the design of new inhibitors of pgp and mrp1 to control multidrug resistance (mdr). Curr Drug Targets. 2006;7:893–909.CrossRefPubMedGoogle Scholar
  16. 16.
    Breier A, Stetka J, Bohacova V, Macejova D, Brtko J, Sulova Z. Effect of 9-cis retinoic acid and all-trans retinoic acid in combination with verapamil on p-glycoprotein expression in l1210 cells. Neoplasma. 2014;61:553–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism of modulation of human p-glycoprotein (abcb1) by curcumin i, ii, and iii purified from turmeric powder. Biochem Pharmacol. 2004;68:2043–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault JM, de Wet H, Maitrejean M, Comte G, Boumendjel A, Mariotte AM, Dumontet C, McIntosh DB, Goffeau A, Castanys S, Gamarro F, Barron D. Modulation by flavonoids of cell multidrug resistance mediated by p-glycoprotein and related abc transporters. Cellular and Molecular Life Sciences: CMLS. 2002;59:307–22.CrossRefPubMedGoogle Scholar
  19. 19.
    Infed N, Smits SH, Dittrich T, Braun M, Driessen AJ, Hanekop N, Schmitt L. Analysis of the inhibition potential of zosuquidar derivatives on selected bacterial and fungal abc transporters. Mol Membr Biol. 2013;30:217–27.CrossRefPubMedGoogle Scholar
  20. 20.
    Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist tariquidar (xr9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2011;17:569–80.CrossRefGoogle Scholar
  21. 21.
    Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. A phase i, randomized, open-label, parallel-cohort, dose-finding study of elacridar (gf120918) and oral topotecan in cancer patients. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2007;13:3276–85.CrossRefGoogle Scholar
  22. 22.
    Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase i/ii trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (ly335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leukemia & Lymphoma. 2007;48:708–15.CrossRefGoogle Scholar
  23. 23.
    Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, Carrillo-Hernandez JF, Pastelin-Hernandez G, Picazo-Picazo O, Ceballos-Reyes G. Proliferation and apoptosis of hela cells induced by in vitro stimulation with digitalis. Eur J Pharmacol. 2006;534:71–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G. Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta. 1768;2007:1691–702.Google Scholar
  25. 25.
    Ramu A, Ramu N, Gorodetsky R. Reduced ouabain-sensitive potassium entry as a possible mechanism of multidrug-resistance in p388 cells. Biochem Pharmacol. 1991;42:1699–704.CrossRefPubMedGoogle Scholar
  26. 26.
    Fiebig HH, Berger DP, Winterhalter BR, Plowman J. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat Rev. 1990;17:109–17.CrossRefPubMedGoogle Scholar
  27. 27.
    Lin CF, Wan SW, Chen MC, Lin SC, Cheng CC, Chiu SC, Hsiao YL, Lei HY, Liu HS, Yeh TM, Lin YS. Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Laboratory Investigation; a Kournal of Technical Methods and Pathology. 2008;88:1079–89.CrossRefGoogle Scholar
  28. 28.
    Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63:12–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Ding XW, Wu JH, Jiang CP. Abcg2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010;86:631–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Podolski-Renic A, Andelkovic T, Bankovic J, Tanic N, Ruzdijic S, Pesic M. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2011;65:345–53.CrossRefGoogle Scholar
  31. 31.
    Chen J, Wang R, Zhang K, Chen LB. Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets. J Cell Mol Med. 2014;18:2425–36.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wang TH, Wan JY, Gong X, Li HZ, Cheng Y. Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Oncol Rep. 2012;28:1681–6.PubMedGoogle Scholar
  33. 33.
    Jansson L, Kim GS, Cheng AG. Making sense of Wnt signaling-linking hair cell regeneration to development. Front Cell Neurosci. 2015;9:66.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.CrossRefPubMedGoogle Scholar
  35. 35.
    Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. Acquisition of chemoresistance and emt phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2011;17:2350–60.CrossRefGoogle Scholar
  36. 36.
    Rosano L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A. Endothelin a receptor/beta-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 2014;74:7453–64.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhang H, Jing X, Wu X, Hu J, Zhang X, Wang X, Su P, Li W, Zhou G. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of fzd1 and mdr1 genes. Anti-Cancer Drugs. 2015;26:706–15.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Radiotherapy and OncologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Institute of Radiotherapy and OncologySoochow UniversitySuzhouChina
  3. 3.Suzhou Key Laboratory for Radiation OncologySuzhouChina
  4. 4.Department of OncologyAffiliated Haian Hospital of Nantong UniversityNantongChina
  5. 5.Laboratory Animal Center of Nantong UniversityNantongChina

Personalised recommendations